For information on intellectual property and technology licensing, including information on LICR spin-off companies, please go to the "Commercialization" section of this Web site.
Download a Fact Sheet on the Ludwig Institute for Cancer Research Ltd: LICR_Fact_sheet.pdf
For media queries, please contact:
Rachel Steinhardt, Communications Director
[+1] 212 450 1582 - Business hours, EST (GMT -5 hours)
Email: Rachel Steinhardt
January 30, 2012
TDO Enzyme Enables Tumors to Avoid Detection and Rejection by the Immune System
New York, NY, January 30, 2012 - Scientists from the Ludwig Institute for Cancer Research (LICR) in Brussels identified a new target for cancer therapy, an enzyme which prevents the immune system from recognizing and destroying certain types of tumors. Called tryptophan 2,3-dioxygenase or TDO, the enzyme works by depriving immune cells of tryptophan, an amino acid essential to their activity. TDO is produced by a significant number of human tumors. Scientists also show that blocking TDO activity with a novel TDO inhibitor promotes tumor rejection in mice. The study findings were published online today in the January 30 issue of the Proceedings of the National Academy of Sciences (PNAS).